Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy

• Hoofdauteurs: Stijn Hentzen (Auteur), Kathan Mehta (Auteur), Raed Moh'd Taiseer Al-Rajabi (Auteur), Anwaar Saeed (Auteur), Joaquina Celebre Baranda (Auteur), Stephen K. Williamson (Auteur), Weijing Sun (Auteur), Anup Kasi (Auteur)
• Formaat: Boek
• Gepubliceerd in: Open Exploration Publishing Inc., 2023-06-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Aim: 177Lu-Dotatate (Lu-177), a form of peptide receptor radionuclide therapy (PRRT), was approved by Food and Drug Administration (FDA) for the treatment of somatostatin-receptor-positive neuroendocrine tumors (NETs) in 2018. Clinical trials prior to the FDA approval of Lu-177 showed favorable outc...